- Mr. Todd Martensen joins KLOX as Chief Commercial Officer
- Mr. Mariano Rodriguez named SVP, Corporate Development and Chief Financial Officer
- KLOX in-gear to kick-start commercialization of its recently approved wound healing treatment system in Europe
LAVAL, QC, Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the "Company") is pleased to announce the following appointments:
Todd Martensen has been hired to KLOX's leadership team in the newly created role of Chief Commercial Officer, to oversee KLOX's commercial launch of LumiHeal™, a BioPhotonic system using topical photoconverter gel for the treatment of chronic and other hard-to-heal wounds, as well as surgical and traumatic wounds, recently approved in Europe. Mr. Martensen, a seasoned executive with more than 20 years of sales, marketing and international commercialization experience, will be supported in the sales and marketing strategy and deployment by David Burroughes, Head of Wound Healing, and Leonardo Borghesio, General Manager of KLOX Italia, both of whom have extensive marketing and commercial experience in wound healing.
KLOX is also pleased to announce that Mariano Rodriguez, CA, CPA, has been promoted to the position of Senior Vice-President, Corporate Development and Chief Financial Officer.
"With these senior management appointments, we believe KLOX is well-positioned to manage and support our increasing revenues, strong partnerships and an expanding portfolio of approved treatments in markets around the world," said Dr. Lise Hébert, President and Chief Executive Officer of KLOX. "We are pleased that Todd joined us, as he brings a significant depth of commercial experience to our company and he will be heading all commercial activities with an initial focus on the commercialization of our wound healing products. Mariano's appointment is in recognition of both the role he has played and the increasing responsibilities he will be managing in corporate development and finance activities for our growing company," she added.
Mr. Martensen has over 20 years of experience in medical devices and pharmaceuticals, and 13 years of executive-level management experience with both Fortune 25 companies and growth companies. Most recently, he was vice-president responsible for sales in the Americas for the medical division of Chicago-based Leica Microsystems (part of Danaher), a position he held since 2010. From 2005, he was senior vice-president, sales & marketing, at Alveolus, a growth-stage medical device company that was subsequently sold to Merit Medical Systems in late 2009. Prior to that, he was vice-president, sales, at B. Braun Inc. Mr. Martensen began his career with Cordis, a Johnson & Johnson-owned company where he rose through the sales, marketing and operational ranks from 1993 to 2003.
Having been part of KLOX's senior management team since August 2011, as vice president, chief of finance and operations and corporate secretary, Mariano Rodriguez, CA, CPA, has over 20 years of experience in corporate finance with publicly-listed and private companies. He has extensive experience in successful equity and debt financings, business development transactions, as well as international mergers and acquisitions. Before joining KLOX, he served as executive vice-president and chief financial officer of GFI Solutions Group, an IT software and services company from 2009 to 2011. Prior to that, he was vice-president and chief financial officer of Neurochem and Galileo Genomics as well as vice-president, finance and administration, of Bibliomondo Inc. Mr. Rodriguez began his career with Ernst & Young in 1991 and subsequently was the global director of finance for Phoenix International.
About KLOX Technologies
KLOX is a life sciences specialty pharmaceutical company based in Laval, Quebec, Canada. KLOX is focused on the development and commercialization of treatment systems employing its non-invasive BioPhotonic platform, with a focus on the dermatological, wound care and oral health markets.
About KLOX treatments
LumiCleanse™, approved as a medical device for the treatment of all stages of acne vulgaris in Canada and Europe, is being commercialized by Sandoz in Canada and we expect it will be commercially introduced by LEO Pharma in select European markets in 2015. LumiBel™, a cosmetic skin care treatment system is expected to be made available in these markets through the same commercialization partners.
LumiHeal™, approved for chronic and other hard-to-heal wounds in Europe, is expected to be commercialized independently by KLOX in Europe beginning in 2015.
KLOX continues to develop its multi-application pipeline for other potential indications in dermatology, wound care and oral health.
Forward Looking Statements
Certain statements contained in this press release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond KLOX Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which KLOX Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from KLOX Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.
SOURCE KLOX Technologies Inc.